



## Prior Authorization Approval Criteria

### Natroba (Spinosad)

<b>Generic name:</b>	Spinosad
<b>Brand name:</b>	Natroba
<b>Medication class:</b>	Pediculocides
<b>FDA-approved uses:</b>	topical treatment of head lice infestation in patients 4 years and older.
<b>Available dosage forms:</b>	0.9% Topical suspension
<b>Usual dose:</b>	Depending on hair length, up to 120 mL (1 bottle) may be required to adequately cover the hair. The suspension should be left on the hair and scalp for 10 minutes and then rinsed off with warm water. Treatment should be repeated in 7 days if live lice are observed.
<b>Approximate cost:</b> (based on AWP 2011)	\$262.80/bottle
<b>Duration of therapy:</b>	one time treatment unless live lice are observed in which case treatment should be repeated 7 days after initial treatment.

**Criteria for use** (bullet points below are all inclusive unless otherwise noted):

- The indicated diagnosis (including any applicable labs and /or tests) and medication usage must be supported by documentation from the patient's medical records.
- Must have *Pediculus humanus capitis* (head lice and their ova) of the scalp hair
- Must be 4 years of age or over
- Must have tried and failed/intolerant to OTC permethrin (Nix) or OTC pyrethrins (Rid or similar product)

**Criteria for continuation of therapy:**

- Approved only for a second treatment if live lice present 7 days following the initial treatment.

**Contraindication:**

- None at this time

**Not approved if:**

- Patient does not meet the above criteria

**Special considerations:**

- This topical suspension is thought to exhibit both pediculocidal and ovicidal activity.

FCHP Pharmacy and Therapeutics Committee approval: \_\_\_\_\_

Date: \_\_\_\_\_

Adopted: 09/07/11